This is early beta for now! Can't handle all templates properly
Hankkija
Vastaanotettu Hilmaan | 2019-12-31 |
Ilmoituksen numero | 2019-008936 |
TED numero | 2019/S 080-191763 |
Ostajaorganisaatio | National Institute for Health and Welfare (2229500-6 ) PL 30 FI-00271 Helsinki https://thl.fi/en/web/thlfi-en |
Hankinnan otsikkotiedot | Human Papillomavirus Vaccine (HPV) 2019-2020 (2020-2021) |
Hankinnan yhteenlaskettu kokonaisarvo koko ajalle (ilman alv:ta) arvio | |
Hankinnan yhteenlaskettu kokonaisarvo koko ajalle (ilman alv:ta) lopullinen | 1 447 600 EUR |
Alkuperäinen ilmoitus | https://www.hankintailmoitukset.fi/fi/public/procurement/11303/notice/21391/overview |
Originaali JSON tietue | 21391.json |
Ostettava
Hankinnan lyhyt kuvaus | The purpose of STM and the Customer is to procure Human Papillomavirus Vaccine (HPV) required for the National Vaccination Programme in Finland. The Customer will implement the procurement on STM´s side. The roles of STM and Customer are described in more detail in section "Presentation of the contracting authority". The contract will be awarded to one Supplier based on a comparison of tenders. Estimated quantity for the contract period is 47 000 doses. The customer reserves the right to increase or decrease the ordered numbers of doses by up to 20%. The estimated duration of the contract is about one year. After the contract period, the Customer reserves the right for the option described in section "Information about additional procurement options". Please notice that in the section "II.2.5. Award criteria" Price means the reference price. Tenders will be compared in the manner described in section "Grounds for decision" of the Invitation to tender. |
Hankintanimikkeistö (CPV) pää | |
Hankintanimikkeistö (CPV) muut | |
Aluekoodi | FI |
Pääasiallinen suorituspaikka |
Sopimukset
Päätös päivämäärä | 2019-03-25 |
Sopimusnumero | |
Myyjät | GlaxoSmithKline Oy (FI), 0108378-4 |